Genmab — April 2018

Bulder

PBD

Sukkeralf

Det er nok mere komplekst end som så - tænker mest linkeren, men man skal nok grave lidt dybere i det. Som jeg husker det er PBD warheads ca. 1000 gange mere potent end eksempelvis MMAE, så det kræver jo at giften i endnu højere grad leveres det rette sted

Bulder

Av, det var voldsomt. Nu var lungeødem et af problemerne. Hvordan ser det ud med cd25 i lungerne - ved du det?

Bulder

Jeg kan se, Genmab skriver: limited expression on normal tissues

Sukkeralf

Det er vel noget i stil med dette Jan mener er problemet med CD38-ADC, at CD38 er udtrykt i lungerne

Bulder

Jeg har et spm til ham, om hvordan han ser på en dara adc sammen med actinium, som jo har haft et par fine abstracts på det seneste.

Bulder

... eller ARC, som det vist hedder, når det er noget radioaktivt, der kobles på mAb'en.

E_L

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells
http://clincancerres.aacrjournals.org/content/early/2018/04/17/1078-0432.CCR-17-3117

E_L

are they now suggesting to take NK cells from daratumumab-treated patients, expand them in the lab, and infuse them into new patients before treatment with Dara?

Bulder

We discussed a similar issue 5. of March. The problem is that dara is killing NK-cells as they express cd38. Not good, as NK-cells were supposed til kill cancer. To overcome this problem it has been suggested to transplant fresh NK-cells from healthy donors. Now they suggest - as I understand it - to take NK-cells from
(other) dara-treated patients, as they mainly contain cd38-low NK-cells (the cd38-high NK-cells are depleted), and infuse them in patients.

Sukkeralf

Fra Roches Q1. while revenue from Ocrevus reached 479 million francs ($487 million), besting analyst estimates of 406 million francs ($413 million).

Sukkeralf

Det ligner en dobbelt BB i år - så lad os få ofatumumab på banen og stjæle den ene BB

E_L

thanks Bulder. It is fascinating, but difficult...

Bulder

Bowers har anslået i et skriv, at ofa i ms kan nå et peaksale på 3.8 mia $ (23,2 mia DKK).

E_L

that would be awesome. "Sellside consensus compiled by EvaluatePharma shows 2022 revenue of $572m for OMB157 versus a still optimistic $267m for Arzerra, and Leerink reckons ofatumumab’s MS incarnation could be generating blockbuster sales by 2026." http://www.epvantage.com/Universal/View.aspx?type=Story&id=740722&isEPVantage=yes

Bulder

Thanks E L. Good article.

pauly

God artikel der også viser os MS indikationen ikke er nem. Men er du gal det ville være dejligt hvis det lykkedes

pauly

og Tak EL

E_L

thinking about the JNJs PD1 plus dara i fase 2/3 you guys discussed yesterday; Opdivo also did really well Q1. "$BMY Q1 Opdivo $1533M big beat vs. consensus of $1374M"

E_L

easy to understand JNJ wants to rush to get part of that...